98%
921
2 minutes
20
The aim of this study was to explore the high-risk factors for recurrence in patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing definitive chemoradiotherapy or radiotherapy (dCRT or dRT). Conditional survival (CS) was used to evaluate the dynamic survival and recurrence risk of patients after treatment, and individualized monitoring strategies were developed for patients. Logistic regression analysis was performed to determine independent recurrence risk factors. Calibration curves and receiver operating characteristic (ROC) curve were used to evaluate nomogram models. Kaplan-Meier curves were used to compare survival rates in different groups and to calculate CS rate. A total of 677 patients were included. Multivariate logistic analyses demonstrated that chemotherapy cycles, tumor length, body mass index (BMI), platelet-lymphocyte ratio (PLR), and lymphocyte-monocyte ratio (LMR) were independent recurrence risk factors (p < 0.05). Subsequently, we constructed nomogram models to predict recurrence and risk stratification. Kaplan-Meier curves showed that conditional locoregional recurrence-free survival and distant metastasis-free survival of patients in different risk groups and clinical stages progressively increased with survival time, whereas local recurrence and distant metastasis annual recurrence rates decreased yearly with increasing survival time. Finally, we developed an individualized follow-up strategy based on CS at different frequencies. Individualized follow-up strategies developed on the basis of CS can better monitor the changes in patients' conditions and contribute to timely salvage treatment and rational allocation of healthcare resources.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695730 | PMC |
http://dx.doi.org/10.1038/s41598-024-84099-4 | DOI Listing |
Catheter Cardiovasc Interv
September 2025
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Patent foramen ovale (PFO) has been identified as a potential risk factor for cryptogenic stroke (CS). Although transesophageal echocardiography (TEE) is considered the gold standard for PFO detection, false-negative results remain a clinical concern, particularly in CS patients with high suspicion of PFO-related etiology.
Aims: To evaluate the clinical utility of transcatheter PFO exploration (TPFOE) in CS patients with negative TEE findings but high suspicion of PFO-related etiology.
Clin Breast Cancer
August 2025
Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Electronic address:
Background: Triple-negative breast cancer (TNBC) carries a substantial risk of recurrence and metastasis, posing significant threats to patients' health and quality of life. Centrosomal protein 55 (CEP55) has been demonstrated to exhibit elevated expression levels in TNBC. However, its molecular regulatory mechanism in TNBC remains unclear.
View Article and Find Full Text PDFJ Int Med Res
September 2025
Obstetrics and Gynecology Department, Wuhan University Zhongnan Hospital, China.
ObjectiveThis study aimed to evaluate the efficacy and safety of hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) in patients with advanced ovarian cancer.MethodsA total of 200 patients with advanced ovarian cancer were enrolled in this retrospective study and randomly allocated to two groups (research registry number: 11353). On the first day after abdominal closure, routine treatment was performed in the non-HIPEC group, whereas HIPEC was performed in the HIPEC group.
View Article and Find Full Text PDFJMIR Res Protoc
September 2025
Department of Medical Oncology, Early Phase Unit, Georges-François Leclerc Centre, Dijon, France.
Background: Sarcomas are rare cancer with a heterogeneous group of tumors. They affect both genders across all age groups and present significant heterogeneity, with more than 70 histological subtypes. Despite tailored treatments, the high metastatic potential of sarcomas remains a major factor in poor patient survival, as metastasis is often the leading cause of death.
View Article and Find Full Text PDFJ Pediatr Hematol Oncol
September 2025
Department of Pediatric, The University of Jordan.
Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.
View Article and Find Full Text PDF